Alzheimer’s Disease Diagnostics Market Size, Share & Trends Analysis Report By Diagnostics Technique (Biomarkers, Imaging Techniques, Genetic Testing, Cognitive Assessment Tests), By Type (Triage, Diagnosis, Screening), By End User, By Region And Segment
Description
Alzheimer’s Disease Diagnostics Market Summary
TThe global Alzheimer's disease diagnostics market size was estimated at USD 9.22 billion in 2025 and is expected to reach USD 21.54 billion by 2033, projected to grow at a CAGR of 11.23% from 2026 to 2033. Increasing prevalence of Alzheimer’s Disease (AD), growing use of biomarkers in disease diagnostics, growing adoption of personalized products, and increasing technological advancements in medical imaging are some of the factors expected to drive the demand for Alzheimer’s diagnostics.
Increasing government investments and R&D studies is further propelling growth. The rising prevalence of Alzheimer's disease is a key driver of market growth. As the global population ages, the demand for early and accurate diagnostic tools continues to increase. According to the 2024 Alzheimer's Association, dementia risk rises with age, and the number of Americans with Alzheimer's is expected to grow significantly. By 2050, the population aged 65 and older is projected to reach 82 million, up from 58 million in 2022. By 2030, all baby boomers (born between 1946 and 1964) will be 65 or older, the age group most susceptible to Alzheimer's dementia.
In recent years, there has been significant progress in developing novel therapeutic drugs targeting the root causes of Alzheimer’s disease. In January 2023, the U.S. FDA granted accelerated approval to lecanemab, a treatment co-developed by Eisai Co., Ltd. and Biogen Inc. Eisai also applied for manufacturing and marketing approval in Japan, where the drug received priority review from the Ministry of Health, Labour and Welfare (MHLW). However, effective use and distribution of these drugs require technology to detect amyloid-beta (Aβ) accumulation in the brain. Conventional testing methods, such as cerebrospinal fluid (CSF) testing and amyloid PET scans, are costly and invasive, increasing the demand for simpler, less invasive diagnostic approaches.
The growing global burden of Alzheimer’s has intensified the need for early detection and precise diagnosis. Advances in genomics, proteomics, and metabolomics have expanded the use of biomarkers in disease diagnostics. Biomarkers, particularly those detecting amyloid-beta and tau proteins in CSF through positron emission tomography (PET) imaging, play a crucial role in Alzheimer’s diagnosis. In addition, companies are launching innovative biomarker tests to support ongoing clinical trials. In March 2024, Labcorp introduced the pTau217 blood biomarker test, designed to accelerate Alzheimer’s diagnosis and improve clinical trial efficiency. This test is expected to enhance the accuracy and speed of detecting Alzheimer’s, ensuring timely treatment and disease management.
The rise of personalized medicine has underscored the importance of biomarkers in patient categorization, treatment selection, and therapeutic monitoring. This trend is expected to drive the biomarkers market’s expansion. A 2023 study published in the Journal of Alzheimer's Disease emphasized the role of precision medicine in Alzheimer’s, considering genetic, environmental, and lifestyle factors in disease progression. Similarly, an October 2021 study suggested bumetanide, an FDA-approved oral diuretic, as a potential treatment for Alzheimer’s. Research funded by the National Institute on Aging (NIA) analyzed brain tissue samples and FDA-approved drugs to explore repurposing opportunities, highlighting precision medicine’s potential in Alzheimer’s treatment.
Advancements in image analysis and machine learning algorithms have enhanced the accuracy and reliability of Alzheimer’s diagnostics through neuroimaging techniques. Diagnostic approaches have evolved from traditional cognitive assessments to advanced neuroimaging and CSF assays, allowing for early disease identification. In June 2023, Roche received FDA clearance for its CSF assay, which aids in timely diagnosis and treatment decision-making by measuring beta-amyloid and tau protein levels, two key biomarkers of Alzheimer’s pathology, in individuals aged 55 and older. These technological advancements are crucial for improving Alzheimer’s detection and management.
Ongoing research and technological innovations are driving the expansion of the Alzheimer’s diagnostics and therapeutics market. Companies continue to introduce new tests and products while engaging in strategic collaborations, mergers, and investments. A February 2024 MedPage Today article highlighted the diagnostic potential of blood biomarkers in Alzheimer’s research and clinical applications. Key industry players are advancing blood biomarker technologies to enhance global diagnostic capabilities. In August 2023, C2N Diagnostics launched the PrecivityAD2 blood test, designed to match the accuracy of PET scans and CSF tests. This test aims to assess patients with cognitive decline and Alzheimer’s symptoms, further strengthening diagnostic advancements in the field.
Global Alzheimer’s Disease Diagnostics Market Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the global Alzheimer’s disease diagnostics market report on the basis of diagnostics technique, type, end use, and region.
TThe global Alzheimer's disease diagnostics market size was estimated at USD 9.22 billion in 2025 and is expected to reach USD 21.54 billion by 2033, projected to grow at a CAGR of 11.23% from 2026 to 2033. Increasing prevalence of Alzheimer’s Disease (AD), growing use of biomarkers in disease diagnostics, growing adoption of personalized products, and increasing technological advancements in medical imaging are some of the factors expected to drive the demand for Alzheimer’s diagnostics.
Increasing government investments and R&D studies is further propelling growth. The rising prevalence of Alzheimer's disease is a key driver of market growth. As the global population ages, the demand for early and accurate diagnostic tools continues to increase. According to the 2024 Alzheimer's Association, dementia risk rises with age, and the number of Americans with Alzheimer's is expected to grow significantly. By 2050, the population aged 65 and older is projected to reach 82 million, up from 58 million in 2022. By 2030, all baby boomers (born between 1946 and 1964) will be 65 or older, the age group most susceptible to Alzheimer's dementia.
In recent years, there has been significant progress in developing novel therapeutic drugs targeting the root causes of Alzheimer’s disease. In January 2023, the U.S. FDA granted accelerated approval to lecanemab, a treatment co-developed by Eisai Co., Ltd. and Biogen Inc. Eisai also applied for manufacturing and marketing approval in Japan, where the drug received priority review from the Ministry of Health, Labour and Welfare (MHLW). However, effective use and distribution of these drugs require technology to detect amyloid-beta (Aβ) accumulation in the brain. Conventional testing methods, such as cerebrospinal fluid (CSF) testing and amyloid PET scans, are costly and invasive, increasing the demand for simpler, less invasive diagnostic approaches.
The growing global burden of Alzheimer’s has intensified the need for early detection and precise diagnosis. Advances in genomics, proteomics, and metabolomics have expanded the use of biomarkers in disease diagnostics. Biomarkers, particularly those detecting amyloid-beta and tau proteins in CSF through positron emission tomography (PET) imaging, play a crucial role in Alzheimer’s diagnosis. In addition, companies are launching innovative biomarker tests to support ongoing clinical trials. In March 2024, Labcorp introduced the pTau217 blood biomarker test, designed to accelerate Alzheimer’s diagnosis and improve clinical trial efficiency. This test is expected to enhance the accuracy and speed of detecting Alzheimer’s, ensuring timely treatment and disease management.
The rise of personalized medicine has underscored the importance of biomarkers in patient categorization, treatment selection, and therapeutic monitoring. This trend is expected to drive the biomarkers market’s expansion. A 2023 study published in the Journal of Alzheimer's Disease emphasized the role of precision medicine in Alzheimer’s, considering genetic, environmental, and lifestyle factors in disease progression. Similarly, an October 2021 study suggested bumetanide, an FDA-approved oral diuretic, as a potential treatment for Alzheimer’s. Research funded by the National Institute on Aging (NIA) analyzed brain tissue samples and FDA-approved drugs to explore repurposing opportunities, highlighting precision medicine’s potential in Alzheimer’s treatment.
Advancements in image analysis and machine learning algorithms have enhanced the accuracy and reliability of Alzheimer’s diagnostics through neuroimaging techniques. Diagnostic approaches have evolved from traditional cognitive assessments to advanced neuroimaging and CSF assays, allowing for early disease identification. In June 2023, Roche received FDA clearance for its CSF assay, which aids in timely diagnosis and treatment decision-making by measuring beta-amyloid and tau protein levels, two key biomarkers of Alzheimer’s pathology, in individuals aged 55 and older. These technological advancements are crucial for improving Alzheimer’s detection and management.
Ongoing research and technological innovations are driving the expansion of the Alzheimer’s diagnostics and therapeutics market. Companies continue to introduce new tests and products while engaging in strategic collaborations, mergers, and investments. A February 2024 MedPage Today article highlighted the diagnostic potential of blood biomarkers in Alzheimer’s research and clinical applications. Key industry players are advancing blood biomarker technologies to enhance global diagnostic capabilities. In August 2023, C2N Diagnostics launched the PrecivityAD2 blood test, designed to match the accuracy of PET scans and CSF tests. This test aims to assess patients with cognitive decline and Alzheimer’s symptoms, further strengthening diagnostic advancements in the field.
Global Alzheimer’s Disease Diagnostics Market Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the global Alzheimer’s disease diagnostics market report on the basis of diagnostics technique, type, end use, and region.
- Diagnostics Technique Outlook (Revenue, USD Million, 2021 - 2033)
- Biomarkers
- CSF Biomarkers
- Blood-Based Biomarkers
- Imaging Techniques
- Genetic Testing
- Cognitive Assessment Tests
- Type Outlook (Revenue, USD Million, 2021 - 2033)
- Triage
- Diagnosis
- Screening
- End Use Outlook (Revenue, USD Million, 2021 - 2033)
- Hospitals
- Diagnostic Laboratories
- Academic and Research Institutes
- Regional Outlook (Revenue in USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Sweden
- Denmark
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East and Africa
- Saudi Arabia
- South Africa
- UAE
- Kuwait
Table of Contents
150 Pages
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Product
- 1.2.2. Application
- 1.2.3. Route of Administration
- 1.2.4. Distribution Channel
- 1.2.5. Regional scope
- 1.2.6. Estimates and forecasts timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR’s internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
- 1.4.5.1. Data for primary interviews in North America
- 1.4.5.2. Data for primary interviews in Europe
- 1.4.5.3. Data for primary interviews in Asia Pacific
- 1.4.5.4. Data for primary interviews in Latin America
- 1.4.5.5. Data for Primary interviews in MEA
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
- Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Product and Application Outlook
- 2.2.2. Route of Administration and Distribution Channel Outlook
- 2.2.3. Regional outlook
- 2.3. Competitive Insights
- Chapter 3. GLP-1 Receptor Agonist Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.1.1. Increasing prevalence of chronic diseases such as diabetes and obesity
- 3.2.1.2. Increasing R&D activities for developing novel therapeutics
- 3.2.1.3. Formulation advancements of oral GLP-1 receptor agonists
- 3.2.1.4. Increasing awareness about diagnosis and treatment options for diabetes
- 3.2.2. Market restraint analysis
- 3.2.2.1. Product failure
- 3.2.2.2. Patent expiry of blockbuster drugs during the forecast period
- 3.3. GLP-1 Receptor Agonist Market Analysis Tools
- 3.3.1. Industry Analysis - Porter’s
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Technological landscape
- 3.3.2.3. Economic landscape
- 3.4. Pricing Analysis
- 3.5. Pipeline Analysis
- 3.6. Patent Expiry Analysis
- Chapter 4. GLP-1 Receptor Agonist Market: Product Estimates & Trend Analysis
- 4.1. Global GLP-1 Receptor Agonist Market: Product Dashboard
- 4.2. Global GLP-1 Receptor Agonist Market: Product Movement Analysis
- 4.3. Ozempic
- 4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 4.4. Rybelsus
- 4.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 4.5. Trulicity
- 4.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 4.6. Saxenda
- 4.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 4.7. Wegovy
- 4.7.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 4.8. Victoza
- 4.8.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 4.9. Mounjaro
- 4.9.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 4.10. Zepbound
- 4.10.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 4.11. Others
- 4.11.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- Chapter 5. GLP-1 Receptor Agonist Market: Application Estimates & Trend Analysis
- 5.1. Global GLP-1 Receptor Agonist Market: Application Dashboard
- 5.2. Global GLP-1 Receptor Agonist Market: Application Movement Analysis
- 5.3. Type 2 Diabetes Mellitus
- 5.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 5.4. Obesity
- 5.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- Chapter 6. GLP-1 Receptor Agonist Market: Route of Administration Estimates & Trend Analysis
- 6.1. Global GLP-1 Receptor Agonist Market: Route of Administration Dashboard
- 6.2. Global GLP-1 Receptor Agonist Market: Route of Administration Movement Analysis
- 6.3. Parenteral
- 6.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 6.4. Oral
- 6.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- Chapter 7. GLP-1 Receptor Agonist Market: Distribution Channel Estimates & Trend Analysis
- 7.1. Global GLP-1 Receptor Agonist Market: Distribution Channel Dashboard
- 7.2. Global GLP-1 Receptor Agonist Market: Distribution Channel Movement Analysis
- 7.3. Hospital Pharmacies
- 7.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 7.4. Retail Pharmacies
- 7.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 7.5. Online Pharmacies
- 7.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- Chapter 8. GLP-1 Receptor Agonist Market: Regional Estimates & Trend Analysis By Product, Application, Route of Administration, and Distribution Channel
- 8.1. Regional Dashboard
- 8.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
- 8.3. North America
- 8.3.1. U.S.
- 8.3.1.1. Key country dynamics
- 8.3.1.2. Regulatory framework/ reimbursement structure
- 8.3.1.3. Competitive scenario
- 8.3.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
- 8.3.2. Canada
- 8.3.2.1. Key country dynamics
- 8.3.2.2. Regulatory framework/ reimbursement structure
- 8.3.2.3. Competitive scenario
- 8.3.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
- 8.3.3. Mexico
- 8.3.3.1. Key country dynamics
- 8.3.3.2. Regulatory framework/ reimbursement structure
- 8.3.3.3. Competitive scenario
- 8.3.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
- 8.4. Europe
- 8.4.1. UK
- 8.4.1.1. Key country dynamics
- 8.4.1.2. Regulatory framework/ reimbursement structure
- 8.4.1.3. Competitive scenario
- 8.4.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
- 8.4.2. Germany
- 8.4.2.1. Key country dynamics
- 8.4.2.2. Regulatory framework/ reimbursement structure
- 8.4.2.3. Competitive scenario
- 8.4.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
- 8.4.3. France
- 8.4.3.1. Key country dynamics
- 8.4.3.2. Regulatory framework/ reimbursement structure
- 8.4.3.3. Competitive scenario
- 8.4.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
- 8.4.4. Italy
- 8.4.4.1. Key country dynamics
- 8.4.4.2. Regulatory framework/ reimbursement structure
- 8.4.4.3. Competitive scenario
- 8.4.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
- 8.4.5. Spain
- 8.4.5.1. Key country dynamics
- 8.4.5.2. Regulatory framework/ reimbursement structure
- 8.4.5.3. Competitive scenario
- 8.4.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
- 8.4.6. Denmark
- 8.4.6.1. Key country dynamics
- 8.4.6.2. Regulatory framework/ reimbursement structure
- 8.4.6.3. Competitive scenario
- 8.4.6.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
- 8.4.7. Sweden
- 8.4.7.1. Key country dynamics
- 8.4.7.2. Regulatory framework/ reimbursement structure
- 8.4.7.3. Competitive scenario
- 8.4.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
- 8.4.8. Norway
- 8.4.8.1. Key country dynamics
- 8.4.8.2. Regulatory framework/ reimbursement structure
- 8.4.8.3. Competitive scenario
- 8.4.8.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
- 8.5. Asia Pacific
- 8.5.1. Japan
- 8.5.1.1. Key country dynamics
- 8.5.1.2. Regulatory framework/ reimbursement structure
- 8.5.1.3. Competitive scenario
- 8.5.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
- 8.5.2. China
- 8.5.2.1. Key country dynamics
- 8.5.2.2. Regulatory framework/ reimbursement structure
- 8.5.2.3. Competitive scenario
- 8.5.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
- 8.5.3. India
- 8.5.3.1. Key country dynamics
- 8.5.3.2. Regulatory framework/ reimbursement structure
- 8.5.3.3. Competitive scenario
- 8.5.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
- 8.5.4. Australia
- 8.5.4.1. Key country dynamics
- 8.5.4.2. Regulatory framework/ reimbursement structure
- 8.5.4.3. Competitive scenario
- 8.5.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
- 8.5.5. South Korea
- 8.5.5.1. Key country dynamics
- 8.5.5.2. Regulatory framework/ reimbursement structure
- 8.5.5.3. Competitive scenario
- 8.5.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
- 8.5.6. Thailand
- 8.5.6.1. Key country dynamics
- 8.5.6.2. Regulatory framework/ reimbursement structure
- 8.5.6.3. Competitive scenario
- 8.5.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
- 8.6. Latin America
- 8.6.1. Brazil
- 8.6.1.1. Key country dynamics
- 8.6.1.2. Regulatory framework/ reimbursement structure
- 8.6.1.3. Competitive scenario
- 8.6.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
- 8.6.2. Argentina
- 8.6.2.1. Key country dynamics
- 8.6.2.2. Regulatory framework/ reimbursement structure
- 8.6.2.3. Competitive scenario
- 8.6.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
- 8.7. MEA
- 8.7.1. South Africa
- 8.7.1.1. Key country dynamics
- 8.7.1.2. Regulatory framework/ reimbursement structure
- 8.7.1.3. Competitive scenario
- 8.7.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
- 8.7.2. Saudi Arabia
- 8.7.2.1. Key country dynamics
- 8.7.2.2. Regulatory framework/ reimbursement structure
- 8.7.2.3. Competitive scenario
- 8.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
- 8.7.3. UAE
- 8.7.3.1. Key country dynamics
- 8.7.3.2. Regulatory framework/ reimbursement structure
- 8.7.3.3. Competitive scenario
- 8.7.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
- 8.7.4. Kuwait
- 8.7.4.1. Key country dynamics
- 8.7.4.2. Regulatory framework/ reimbursement structure
- 8.7.4.3. Competitive scenario
- 8.7.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)
- Chapter 9. Competitive Landscape
- 9.1. Company/Competition Categorization
- 9.2. Participant Overview
- 9.3. Financial Overview
- 9.4. Product Benchmarking
- 9.5. Company Market Share Analysis, 2025
- 9.6. Strategy Mapping
- 9.7. Company Profiles
- 9.7.1. Eli Lilly and Company.
- 9.7.1.1. Company overview
- 9.7.1.2. Financial performance
- 9.7.1.3. benchmarking
- 9.7.1.4. Strategic initiatives
- 9.7.2. Sanofi
- 9.7.2.1. Company overview
- 9.7.2.2. Financial performance
- 9.7.2.3. benchmarking
- 9.7.2.4. Strategic initiatives
- 9.7.3. Novo Nordisk A/S
- 9.7.3.1. Company overview
- 9.7.3.2. Financial performance
- 9.7.3.3. benchmarking
- 9.7.3.4. Strategic initiatives
- 9.7.4. AstraZeneca.
- 9.7.4.1. Company overview
- 9.7.4.2. Financial performance
- 9.7.4.3. benchmarking
- 9.7.4.4. Strategic initiatives
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
